Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial. EClinicalMedicine.

Investigación y educación

Enviado por remote_content el Lun, 21/10/2024 - 08:43

Enfermedades infecciosas

Álvarez-Moreno C, Yomayusa-González N, Bravo-Ojeda JS, Chacón-Sarmiento J. 20/12/2021

Background
The use of rosuvastatin plus colchicine and emtricitabine/tenofovir in hospitalized patients with SARS-CoV-2 disease (COVID-19) has not been assessed. The objective of this study was to assess the effectiveness and safety of rosuvastatin plus colchicine, emtricitabine/tenofovir, and their combined use in these patients.

Read full article

Artículos que te pueden interesar

Enfermedades infecciosas

Falla D. Citoquinas pro y antiinflamatorias en la infección por SARS-CoV-2, en población de Colombia. Infectio

Noviembre 9, 2020

Enfermedades infecciosas

L.Burden and magnitude of risk in HIV/AIDS in the Colombian health system: A real-world data approach Infectio

Enero 3, 2021

Enfermedades infecciosas

A simplified alternative diagnostic algorithm for SARS-CoV-2 suspected symptomatic patients and confirmed close contacts (asymptomatic): A consensus of Latin American experts. Int J Infect Dis.

Mayo 20, 2021

21 Octubre, 2024